269726-50-3 Usage
Pyridine derivative
The compound is derived from pyridine, a six-membered aromatic heterocyclic compound.
Carbonitrile group
The compound contains a carbonitrile group (CN), a functional group consisting of a carbon atom triple-bonded to a nitrogen atom.
tert-Butyl substituent
The compound has a tert-butyl group (C(CH3)3) attached to the pyridine ring, which is a type of alkyl group.
Highly important intermediate
The compound is a crucial intermediate in the synthesis of various pharmaceutical compounds and agrochemicals.
Potential applications in medicinal chemistry and drug discovery
The compound has the ability to modulate biological targets, making it useful in the development of new drugs and other bioactive molecules.
Versatile building block
The unique structure and reactivity of the compound make it a valuable component in the development of novel drug candidates.
Check Digit Verification of cas no
The CAS Registry Mumber 269726-50-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,6,9,7,2 and 6 respectively; the second part has 2 digits, 5 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 269726-50:
(8*2)+(7*6)+(6*9)+(5*7)+(4*2)+(3*6)+(2*5)+(1*0)=183
183 % 10 = 3
So 269726-50-3 is a valid CAS Registry Number.
269726-50-3Relevant articles and documents
Acrosin structure-based design, synthesis and biological activities of 7-azaindol derivatives as new acrosin inhibitors
Jiang, Jun Hang,Liu, Xue Fei,Zhen, Can Hui,Zhou, You Jun,Zhu, Ju,Lv, Jia Guo,Sheng, Chun Quan
, p. 272 - 275 (2012/01/14)
A series of 7-azaindol derivatives were designed based on the homologous 3D model of human acrosin. These compounds were synthesized and evaluated for their human acrosin inhibitory activities in vitro. Compounds 7a, 7i, 7j, 7k and 7n showed highly inhibitory activity against human acrosin. The three-dimensional structure-activity relationship was investigated through a CoMFA model, which provided valuable information to further study of potential human acrosin inhibitors.
